Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

7.780 +0.150 (+1.97%)
Streaming Delayed Price Updated: 11:55 AM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Why Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Shares of Rush Street Interactive, Inc. (NYSE: RSI) rose sharply in today’s pre-market trading as the company reported better-than-expected fourth-quarter financial results and issued strong revenue... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday to get an idea of the hottest stocks worth watching this morning! 
Via InvestorPlace
Emergent BioSolutions (EBS) Q4 2023 Earnings Call Transcript
EBS earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
EBS Stock Earnings: Emergent BioSolutions Misses EPS, Misses Revenue for Q4 2023
EBS stock results show that Emergent BioSolutions missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Emergent BioSolutions: Q4 Earnings Insights
 
Via Benzinga
Emergent BioSolutions's Earnings: A Preview
 
Via Benzinga
Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?
Investors in Emergent Biosolutions and EBS stock certainly have a big catalyst to cheer today, as the company announced a new CEO. 
Via InvestorPlace
Emergent BioSolutions Reports Q4 Results, Amends Credit Agreement
Emergent BioSolutions reported quarterly losses of 77 cents per share, missing the analyst consensus estimate of losses of 19 cents per share. Quarterly sales came in at $276.6 million which missed the... 
Via Benzinga
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Earnings Scheduled For March 5, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
Via Benzinga
Earnings Scheduled For March 6, 2024
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million. 
Via Benzinga
Earnings Preview For Emergent BioSolutions
 
Via Benzinga
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
What's Going On Emergent BioSolutions Shares Today?
Emergent BioSolutions' shares slide in premarket trading today after ending yesterday's run with a whopping 78% jump. The company announced the appointment of Joseph C. Papa as CEO. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Emergent BioSolutions Inc. (NYSE: EBS) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly... 
Via Benzinga
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
From Emergent BioSolutions
Via GlobeNewswire
Contrarian Calls: 7 Analyst ‘Sell’ Ratings That Should Be ‘Buys’
While it’s usually a good idea to trust Wall Street’s top experts, sometimes, it’s worthwhile to consider contrarian analyst picks. 
Via InvestorPlace
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
From Emergent BioSolutions
Via GlobeNewswire
Why Is Icosavax (ICVX) Stock Up 46% Today?
Icosavax stock is up on Tuesday as investors react to an acquisition deal with AstraZeneca that values ICVX between $15 and $20 per share. 
Via InvestorPlace
EBS Stock Earnings: Emergent BioSolutions Misses EPS, Beats Revenue for Q3 2023
EBS stock results show that Emergent BioSolutions missed analyst estimates for earnings per share but beat on revenue for the third quarter of 2023. 
Via InvestorPlace
What's Going On With Emergent Biosolutions Stock?
Emergent Biosolutions Inc (NYSE: EBS) shares initially traded higher Tuesday before pulling back and turning negative. 
Via Benzinga
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions (EBS) Q3 2023 Earnings Call Transcript
EBS earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.